BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20142849)

  • 21. Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous.
    Dai Y; Wu Z; Wang F; Zhang Z; Yu M
    Biomed Res Int; 2014; 2014():486386. PubMed ID: 25401103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.
    Ambati J; Chalam KV; Chawla DK; D'Angio CT; Guillet EG; Rose SJ; Vanderlinde RE; Ambati BK
    Arch Ophthalmol; 1997 Sep; 115(9):1161-6. PubMed ID: 9298058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Simó R; Lecube A; Segura RM; García Arumí J; Hernández C
    Am J Ophthalmol; 2002 Sep; 134(3):376-82. PubMed ID: 12208249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Ahmad A; Alam K; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
    Acta Ophthalmol; 2018 Jun; 96(4):e460-e467. PubMed ID: 29098793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
    Wang X; Wang G; Wang Y
    Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.
    Praidou A; Klangas I; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S
    Curr Eye Res; 2009 Feb; 34(2):152-61. PubMed ID: 19219687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy.
    Chernykh VV; Varvarinsky EV; Smirnov EV; Chernykh DV; Trunov AN
    Indian J Ophthalmol; 2015 Jan; 63(1):33-6. PubMed ID: 25686060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.
    Loukovaara S; Koivunen P; Inglés M; Escobar J; Vento M; Andersson S
    Acta Ophthalmol; 2014 Jun; 92(4):323-7. PubMed ID: 23718695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema.
    Praidou A; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S
    Acta Ophthalmol; 2011 May; 89(3):248-54. PubMed ID: 19799585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy.
    Hirota K; Keino H; Inoue M; Ishida H; Hirakata A
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):335-42. PubMed ID: 24970617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.
    Byon IS; Jeon HS; Kim HW; Lee SJ; Lee JE; Oum BS
    Curr Eye Res; 2013 Jul; 38(7):774-80. PubMed ID: 23725216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.
    Sun C; Zhang H; Jiang J; Li Y; Nie C; Gu J; Luo L; Wang Z
    Int Ophthalmol; 2020 Feb; 40(2):467-475. PubMed ID: 31802372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy.
    Shen Y; Cao H; Chen F; Suo Y; Wang N; Xu X
    Acta Ophthalmol; 2020 Mar; 98(2):e212-e216. PubMed ID: 31421026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy.
    Kawashima M; Shoji J; Nakajima M; Kamura Y; Sato Y
    Jpn J Ophthalmol; 2007; 51(2):100-4. PubMed ID: 17401618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
    Sydorova M; Lee MS
    Ophthalmic Res; 2005; 37(4):188-90. PubMed ID: 15990461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Funatsu H; Yamashita H; Nakanishi Y; Hori S
    Br J Ophthalmol; 2002 Mar; 86(3):311-5. PubMed ID: 11864890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparative study of vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy].
    Zhou H; Zhang H
    Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):247-50. PubMed ID: 10451953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy.
    Ogata N; Nishikawa M; Nishimura T; Mitsuma Y; Matsumura M
    Am J Ophthalmol; 2002 Sep; 134(3):348-53. PubMed ID: 12208245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy.
    Loukovaara S; Robciuc A; Holopainen JM; Lehti K; Pessi T; Liinamaa J; Kukkonen KT; Jauhiainen M; Koli K; Keski-Oja J; Immonen I
    Acta Ophthalmol; 2013 Sep; 91(6):531-9. PubMed ID: 23106921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.